Navigation Links
Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
Date:9/17/2007

MELBOURNE, Australia, Sept. 17 /PRNewswire-FirstCall/ -- Phosphagenics Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced that, following successful preclinical studies, it plans to undertake a Phase 1 transdermal oxycodone clinical trial aimed at providing chronic pain sufferers with a sustained-release pain management product.

Phosphagenics has submitted all necessary documents for approval of the trial, which is to be conducted at CMAX - an independent clinical research organization located at the Royal Adelaide Hospital. The trial, which will be in up to 30 healthy volunteers, will evaluate the tolerability and safety of the novel transdermal oxycodone. The trial will begin once approval has been received, which is expected within the next six weeks.

The Company is working towards becoming the first to provide chronic pain sufferers with a patch that will provide sustained-release of oxycodone into the bloodstream. Previous clinical trials have demonstrated that Phosphagenics' patented technologies can effectively deliver opiates through the skin without causing any disruption or irritation.

Harry Rosen, Phosphagenics' President and CEO, said: "We have prioritized oxycodone over morphine in our pain management pipeline as we are in commercial discussions with several companies.

"These companies' commercial interests are focused on the license of a transdermal pain product containing oxycodone."

Dr. Esra Ogru, Executive Vice President of Research and Development at Phosphagenics, said: "Our objective is to address a large unmet need by using our technology to deliver oxycodone in a sustained-release formulation to treat pain beyond a 24 hour period."

Oxycodone, currently administered in tablet or intravenous form, in an eight to 12 hour formulation, is more potent than morphine with fewer adverse effects and its worldwide sales exceed $1 billion annually.

About Phosphagenics Limited

Phosphagenics is a
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
3. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
4. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- ScriptPro, of ... of Powers Lake, Wisconsin , ... a distribution and co-marketing agreement allowing ScriptPro to ... throughout the United States . ... management and workflow systems to retail and ambulatory ...
(Date:7/25/2014)... 25, 2014  CVS Caremark Corporation (NYSE: ... Tuesday, August 5, 2014, at 8:30 a.m. (EDT) with ... financial results. An audio webcast of the ... Relations portion of the CVS Caremark website for all ... . This webcast will be archived and available on ...
(Date:7/25/2014)... OF SPAIN, Trinidad and Tobago , July ... Division of the Trinidad & Tobago Ministry of ... market, an innovative therapy that significantly increases the cure ... for patients infected with the genotype 1 virus. ... under the trade brand INCIVO®. ...
Breaking Medicine Technology:ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3
(Date:7/26/2014)... 2014 According to the Metabolic Enhancement ... a comprehensive bodybuilding program that helps men lose body ... steroids . The program also instructs men how to ... , Vkool reveals in its review that this program ... help men get ripped and jacked at the same ...
(Date:7/25/2014)... Staffordshire, UK (PRWEB) July 26, 2014 ... a variety of dental services including general dentistry, clear ... practice opening in September this year in Derby. The ... is at the HollyBrook Medical Centre in Littleover, Derby. ... the new practice. , The new dental practice, which ...
(Date:7/25/2014)... According to a new market ... (vibration monitoring, thermography, ultrasound emission, lubricating oil analysis, ... and Geography - Global Forecast to 2014 - ... market is expected to reach $2.50 at a ... Browse 117 market data Tables and 57 Figures ...
(Date:7/25/2014)... New York, NY (PRWEB) July 25, 2014 ... cut ticket prices across the board for the Guinness ... Liverpool FC and Olympiacos FC at Soldier Field ... is also offering their customer appreciation promo/coupon/offer code SOCCER-2014 ... be an amazing year for diehard soccer fans in ...
(Date:7/25/2014)... USA (PRWEB) July 25, 2014 As reported ... Use, OD Deaths Increase (7/20), Michigan has seen a nearly ... four years. While the count was 271 between 1999 and ... range. DEA Agents believe that, like other states, drug users ... the drug via prescription pills. He compared the price of ...
Breaking Medicine News(10 mins):Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 2Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 3Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Liverpool FC vs. Olympiacos FC Tickets Soldier Field: Ticket Down Slashes Ticket Prices for Guinness International Champions Cup in Chicago on Sunday, July 27th 2Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2
... anxiety experienced by many women after a miscarriage can continue ... according to a study led by University of Rochester Medical ... Journal of Psychiatry . "Our study clearly shows that ... mental health problems that many women experience after a miscarriage ...
... end-stage renal disease who opt for peritoneal dialysis experience no ... a retrospective study at UT Southwestern Medical Center has found. ... body and provides greater mobility than hemodialysis, the more common ... peritoneal dialysis, have a better quality of life and the ...
... of HIV-infected mothers a daily dose of the antiretroviral ... HIV transmission to the infants at age 6 months ... weeks, according to preliminary clinical trial data presented today. ... reduction in HIV transmission risk through breast milk for ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... Drug Administration said Wednesday that it plans to remove ... from pharmacy shelves. These drugs have not been ... they may be riskier to take than approved over-the-counter ...
... , WEDNESDAY, March 2 (HealthDay News) -- Moms-to-be ... oxycodone (Oxycontin) may increase the risk of birth ... report. Taking these types of analgesics just prior to ... to a modest risk of congenital heart defects in an ...
... Tobacco smoking is the leading preventable cause of death and ... year attributable to smoking or its consequences. And yet teens ... and approximately 80 percent of adult smokers became hooked by ... up smoking usually never do. While studies ...
Cached Medicine News:Health News:Women who miscarry continue to have mental health problems 2Health News:Portable, less costly peritoneal dialysis shows no additional catheter risk factors 2Health News:6-month drug regimen cuts HIV risk for breastfeeding infants, NIH study finds 2Health News:6-month drug regimen cuts HIV risk for breastfeeding infants, NIH study finds 3Health News:FDA Bans Unapproved Prescription Cough, Cold and Allergy Meds 2Health News:FDA Bans Unapproved Prescription Cough, Cold and Allergy Meds 3Health News:CDC Links Prescription Painkillers in Pregnancy to Birth Defects 2Health News:Tobacco smoking impacts teens' brains, UCLA study shows 2Health News:Tobacco smoking impacts teens' brains, UCLA study shows 3
TBR-720-2-GD is large capacity upright style operating temperature +4C. It is specially designed refrigerators for the storage of blood in standard 500ml bags, complying with Australian Standard AS38...
DSL-10-49300 is a rapid, direct enzyme immunoassay (EIA) kit that provides materials for the quantitative measurement of testosterone in saliva. This assay requires no sample extraction or pretreat...
... Only 1-2% of circulating testosterone exists as ... 60%, is bound to SHBG with high ... bound to albumin. Both the albumin-bound and ... SHBG effectively inhibits testosterone action. Measurement of ...
RIA kit for the quantitative determination of autoantibodies to steroid 21-hydroxylase (21-OH) in serum....
Medicine Products: